Current status of bronchial asthma and results of asthma control in patients after 3 months of treatment: A longitudinal follow-up study.

IF 2.8 Q3 ALLERGY

Asia Pacific Allergy Pub Date : 2026-04-01 Epub Date: 2025-11-10 DOI:10.5415/apallergy.0000000000000238

Dan Bui Van, Oanh Nguyen Thi, Ha Nguyen Le, Lan Nguyen Thi Thu, Huong Nguyen Thi Mai, Mui Tran Thi, Quan Nguyen Van Hong, Trinh Cao Thi, Hanh Hong Chu, Phuong Nguyen Hoang, Tung Le Dinh

{"title":"Current status of bronchial asthma and results of asthma control in patients after 3 months of treatment: A longitudinal follow-up study.","authors":"Dan Bui Van, Oanh Nguyen Thi, Ha Nguyen Le, Lan Nguyen Thi Thu, Huong Nguyen Thi Mai, Mui Tran Thi, Quan Nguyen Van Hong, Trinh Cao Thi, Hanh Hong Chu, Phuong Nguyen Hoang, Tung Le Dinh","doi":"10.5415/apallergy.0000000000000238","DOIUrl":null,"url":null,"abstract":"Background: Bronchial asthma (BA) is a chronic respiratory disease that significantly affects patients' quality of life if not well managed. The Global Initiative for Asthma (GINA) 2022 guidelines open a new, more effective direction in controlling asthma attacks for patients.Objective: The study was conducted to describe the current status of BA and the results of asthma control in patients after 3 months of treatment.Methods: A prospective longitudinal study was conducted on 47 patients over 12 years old with BA treated at the Department of Allergy, Immunology and Dermatology, Hospital E, from July 2023 to September 2024. The current study assessed BA control after treatment for patients according to GINA 2022 guidelines and the Asthma Control Test (ACT) score.Results: Before treatment, the majority of patients' BA attacks were severe (55.3%) with moderate obstructive ventilatory disorder (42.6%). After treatment, patients' asthma was completely controlled at 93.6%, while respiratory function was significantly improved.Conclusion: After treatment, patients' asthma was well controlled on all 3 assessment scales: GINA 2022 symptom control, ACT score, and respiratory function. Widespread application of GINA 2022 guidelines in BA control in Vietnam is recommended.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"16 2","pages":"100-106"},"PeriodicalIF":2.8000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061055/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.0000000000000238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Bronchial asthma (BA) is a chronic respiratory disease that significantly affects patients' quality of life if not well managed. The Global Initiative for Asthma (GINA) 2022 guidelines open a new, more effective direction in controlling asthma attacks for patients.

Objective: The study was conducted to describe the current status of BA and the results of asthma control in patients after 3 months of treatment.

Methods: A prospective longitudinal study was conducted on 47 patients over 12 years old with BA treated at the Department of Allergy, Immunology and Dermatology, Hospital E, from July 2023 to September 2024. The current study assessed BA control after treatment for patients according to GINA 2022 guidelines and the Asthma Control Test (ACT) score.

Results: Before treatment, the majority of patients' BA attacks were severe (55.3%) with moderate obstructive ventilatory disorder (42.6%). After treatment, patients' asthma was completely controlled at 93.6%, while respiratory function was significantly improved.

Conclusion: After treatment, patients' asthma was well controlled on all 3 assessment scales: GINA 2022 symptom control, ACT score, and respiratory function. Widespread application of GINA 2022 guidelines in BA control in Vietnam is recommended.

查看原文本刊更多论文

支气管哮喘现状及治疗3个月后哮喘控制结果：一项纵向随访研究。

背景：支气管哮喘（BA）是一种慢性呼吸系统疾病，如果管理不善，会严重影响患者的生活质量。全球哮喘倡议（GINA） 2022指南为控制患者哮喘发作开辟了新的、更有效的方向。目的：描述BA患者治疗3个月后的现状及哮喘控制结果。方法：对2023年7月至2024年9月在E医院过敏、免疫和皮肤科治疗的47例12岁以上BA患者进行前瞻性纵向研究。目前的研究根据GINA 2022指南和哮喘控制测试（ACT）评分评估患者治疗后的BA控制。结果：治疗前，BA发作以重度（55.3%）为主，伴中度阻塞性通气障碍（42.6%）。治疗后患者哮喘完全控制率为93.6%，呼吸功能明显改善。结论：治疗后，患者哮喘在GINA 2022症状控制、ACT评分、呼吸功能3个评估量表上均得到较好的控制。建议在越南广泛应用GINA 2022指南控制BA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia Pacific Allergy ALLERGY-

CiteScore

2.50

自引率

5.90%

发文量

期刊介绍： Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.